Recombinant Protein Therapeutics CDMO Market (2026 - 2033)

Recombinant Protein Therapeutics CDMO Market Summary

The global recombinant protein therapeutics CDMO market size was valued at USD 27.0 billion in 2025 and is projected to grow from USD 30.7 billion in 2026 to USD 77.4 billion by 2033, growing at a CAGR of 13.9% from 2026 to 2033. North America dominated the market, accounting for a largest revenue share of 38.0% in 2025. The increasing demand for biological drugs, including recombinant protein therapeutics as an effective option in treating various diseases, is one of the major factors supporting the growth of the recombinant protein therapeutics industry.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

This increased demand is likely to drive the need for CDMOs, which can provide manufacturing & development services for the same. Moreover, advancements in biotechnology, such as the implementation of novel and enhanced technologies & techniques for producing recombinant protein drugs, are another significant factor supporting the market’s growth.

The recombinant protein therapeutics CDMO market is experiencing strong growth, driven by the increasing outsourcing of biologics research, development, and manufacturing by pharmaceutical and biotechnology companies seeking to optimize production costs, accelerate development timelines, and access specialized expertise in biologics manufacturing. The growing demand for monoclonal antibodies, recombinant proteins, enzymes, cytokines, hormones, and other biologics is encouraging companies to partner with CDMOs offering advanced capabilities in cell line development, process development, analytical testing, and large-scale GMP manufacturing.

In addition, the rapid expansion of biologics and biosimilars has transformed the treatment landscape across numerous therapeutic areas. Compared with many conventional small-molecule drugs, biologics offer highly targeted therapeutic approaches for a wide range of chronic and complex diseases. As biologics manufacturing involves complex development, stringent quality requirements, and specialized production processes, pharmaceutical and biotechnology companies are increasingly outsourcing these activities to experienced CDMOs, supporting market growth.

Furthermore, CDMOs are expanding their global manufacturing networks through facility expansions, strategic collaborations, and investments in single-use bioprocessing technologies, continuous manufacturing, automation, and digital process optimization. The increasing adoption of mammalian and microbial expression systems, advancements in upstream and downstream bioprocessing, and growing investments in next-generation biologics, including antibody-drug conjugates (ADCs), bispecific antibodies, fusion proteins, and other engineered recombinant protein therapeutics, are expected to further drive market growth over the forecast period.

Analyst Perspective

The recombinant protein therapeutics CDMO market is expected to grow significantly, driven by the increasing outsourcing of biologics research, development, and manufacturing by pharmaceutical, biotechnology, and emerging biopharmaceutical companies to enhance operational efficiency and optimize production costs. The expanding pipeline of recombinant protein therapeutics across diverse therapeutic areas is anticipated to create significant opportunities for specialized CDMO services spanning cell line development, process development, analytical testing, clinical manufacturing, and commercial-scale production. Furthermore, the growing development of biosimilars and next-generation biologics, increasing investments in biologics and precision medicine, and continuous advancements in cell line engineering, protein expression platforms, and bioprocessing technologies are expected to further accelerate market growth over the forecast period.

Type Insights

The interferons segment led the market, accounting for 21.0% of global revenue in 2025. The segment's growth is driven by the widespread use of recombinant interferons in the treatment of viral infections, multiple sclerosis, and certain cancers. Interferons are cytokine proteins that play a critical role in regulating immune responses and limiting the spread of infections. The three major classes of interferons include interferon-alpha (IFN-α), interferon-beta (IFN-β), and interferon-gamma (IFN-γ). Furthermore, the increasing prevalence of chronic viral infections, autoimmune disorders, and cancer is driving continued research and development of recombinant interferon-based therapeutics. Ongoing advancements in protein engineering and biologics manufacturing are further supporting the development of next-generation interferon therapies, contributing to the growth of this segment.

The growth hormones segment is anticipated to grow at a rapid pace over the forecast period. The segment growth is driven by increasing requirements for proteins that regulate cellular processes and growing demand for treatment in patients with growth hormone deficiency. Moreover, recombinant growth hormones are biologically engineered proteins that are structurally and functionally identical to human growth hormone (somatropin). This recombinant growth hormone further stimulates tissue growth, linear growth (height), and metabolism (protein, carbohydrate, lipid, & mineral). Furthermore, other functions of growth hormones include immunomodulatory actions. Such factors are anticipated to drive the market. For instance, in July 2025, the U.S. FDA approved SKYTROFA (lonapegsomatropin-tcgd) for the treatment of adults with growth hormone deficiency (GHD). SKYTROFA is a long-acting prodrug of somatropin designed for once-weekly administration. This is an excellent example for the recombinant protein therapeutics market.

Source Insights

The mammalian systems segment dominated the market in 2025, accounting for a revenue share of 67.0%. Mammalian cells are used widely for the production of complex human glycoproteins. They offer advantages such as correct protein folding and post-translational modifications. About 60% of therapeutic proteins, especially antibodies, are produced by mammalian cells, and therefore, many CDMOs offer mammalian upstream process development services. Cell lines such as CHO, baby hamster kidney, human embryo kidney, VERO, and HEK293 are widely used for mammalian upstream formulation. For instance, FUJIFILM Biotechnologies offers its ApolloX mammalian expression system, a CHO-based platform designed to accelerate cell line development and commercial manufacturing of monoclonal antibodies, fusion proteins, and other recombinant proteins, improving development timelines and manufacturing efficiency.

The microbial systems segment is expected to grow over the forecast period. Microbial expression systems are extensively used for the production of recombinant protein therapeutics owing to their rapid growth, scalability, and cost-effectiveness. The development of microbial expression systems involves the selection of suitable host cell lines, expression vectors, and optimized process parameters, with host cells genetically engineered to express the target recombinant protein. In addition, microbial systems provide high productivity and consistent batch-to-batch performance, making them a preferred choice for biopharmaceutical companies involved in the development and commercial manufacturing of recombinant protein therapeutics.

Indication Insights

The metabolic disorders segment accounted for a 21.5% share in 2025. The growth of this segment can be attributed to the increasing prevalence of metabolic disorders globally. Factors such as the growing aging population, unhealthy lifestyle changes, rapid urbanization, and rising research activities in recombinant protein therapeutics are contributing to market growth. The increasing burden of metabolic disorders is expected to drive the development of recombinant protein therapeutics for the treatment of these conditions.

The oncology segment is expected to grow during the forecast period. Recent advancements have expanded the application of recombinant protein therapeutics in cancer treatment. These therapeutics are increasingly used as part of combination therapies for various types of cancer. In addition, the expanding pipeline of recombinant protein therapeutics is encouraging companies to accelerate product development. Recombinant protein therapeutics enable the large-scale production of biologically active proteins with improved therapeutic efficacy and safety, supporting their growing adoption in oncology.

Regional Insights

North America dominated the market for recombinant protein therapeutics CDMO and accounted for the largest revenue share of 38.0% in 2025. A high share of the region is mainly due to the U.S. being established as a global leader in the production of recombinant protein drugs. The country has a strong research & development infrastructure and a robust biopharmaceutical industry, which has contributed to its prominence in this field. Furthermore, the U.S. has a sophisticated and well-developed manufacturing infrastructure for biopharmaceuticals, including recombinant protein therapeutics. This infrastructure includes advanced manufacturing technologies, large-scale production facilities, and stringent quality control processes. For instance, in April 2025, Regeneron Pharmaceuticals signed an agreement with FUJIFILM Diosynth Biotechnologies worth more than USD 3 billion for the expansion of manufacturing of commercial biologic drugs in the U.S. in Holly Springs, North Carolina. This contract helped Regeneron Pharmaceuticals to increase its capacity to manufacture large-scale biologics in the U.S. by almost double.

To learn more about this report, Download Free Sample Report

U.S. Recombinant Protein Therapeutics CDMO Market Trends

The recombinant protein therapeutics CDMO market in the U.S. held the largest share in 2025. An increase in R&D activities and a rise in the number of drug approvals in the country are among the major factors supporting market growth. Furthermore, pharmaceutical companies in the region are collaborating with other companies to outsource business activities to improve the cost-efficiency of production and focus more on product innovation. In addition, the presence of leading biologics developers and continuous investments in advanced biomanufacturing technologies are further strengthening demand for recombinant protein CDMO services.

Europe Recombinant Protein Therapeutics CDMO Market Trends

The recombinant protein therapeutics CDMO industry in Europe is expected to grow significantly owing to the presence of key pharmaceutical and biotechnology companies in this region. In addition, there is a large number of CDMOs specializing in therapy innovation in various European countries like the UK, Germany, and France, which is expected to contribute to market growth in this region. Moreover, increasing investments in biologics manufacturing infrastructure and supportive regulatory frameworks for advanced therapeutics are driving outsourcing activities across the region.

The recombinant protein therapeutics CDMO market in the UK is anticipated to grow over the forecast period. The market growth can be attributed to various factors, such as the presence of various multinational CDMOs, significant R&D spending, growing healthcare research, and rapidly evolving therapeutic approaches. In addition, increasing collaborations between academic institutions, biotechnology companies, and CDMOs are accelerating the development and commercialization of recombinant protein therapeutics.

Germany recombinant protein therapeutics CDMO market held the largest share in 2025, owing to increased requirements for improved product designs and related services in the country, which is expected to be a key factor driving market growth in the coming years. Advancements in technology and quality clinical resources are some of the key factors expected to propel market growth over the forecast period. Furthermore, Germany's strong biopharmaceutical manufacturing base and continued investments in bioprocessing technologies are supporting the expansion of recombinant protein production and contract manufacturing services.

Asia Pacific Recombinant Protein Therapeutics CDMO Market Trends

Asia Pacific recombinant protein therapeutics CDMO market is expected to grow during the forecast period. The regional growth can be attributed to various amendments made by regulatory organizations to change clinical trial evaluation standards according to global requirements, as well as various major players investing in Asia Pacific. Furthermore, the changing business model of MNC outsourcing and R&D activities is expected to propel recombinant protein therapeutics CDMO demand in the Asia Pacific owing to the cost-efficiency offered by CDMOs in countries such as India and China. These countries are expected to witness lucrative growth in the market, whereas countries such as South Korea, Australia, and Thailand are also expected to witness steady growth. The establishment of several CDMOs across the Asia Pacific region has also strengthened innovation in therapies in the region. For instance, in July 2025, WuXi Biologics announced the start of construction of a modular Drug Product (DP) facility at its Singapore CRDMO hub. Once completed, it will be one of the world's largest modular biologics DP facilities, with operations expected in 2027. It will further augment the firm’s manufacturing capacities for biologics and positioning the Asia Pacific region as the global hub for recombinant protein therapeutics CDMOs.

The recombinant protein therapeutics CDMO market in China held the largest share in 2025 due to rising investments, growing adoption of R&D standards, and robust demand for CDMOs. In addition, the country has witnessed growth in the demand for recombinant proteins in various disease studies. Furthermore, supportive government policies aimed at strengthening domestic biopharmaceutical manufacturing and expanding biologics production capacity are accelerating the growth of recombinant protein CDMO services.

Japan recombinant protein therapeutics CDMO market is expected to grow over the forecast period due to numerous factors such as the growing pharmaceutical industry, increasing demand for outsourcing services, and rising R&D activities. In addition, with growing R&D and demand for CDMOs, several drug candidates are in the pipeline. The presence of well-established pharmaceutical companies and increasing development of biologics and biosimilars are further driving demand for specialized recombinant protein manufacturing services.

The recombinant protein therapeutics CDMO market in India is anticipated to grow at the fastest CAGR over the forecast period, owing to low labor costs, improved infrastructure, and a large number of technical experts, which are some of the major factors driving market growth. Moreover, increasing investments by global biopharmaceutical companies and the expansion of GMP-compliant biologics manufacturing facilities are strengthening India's position as a preferred outsourcing destination for recombinant protein therapeutics.

Key Recombinant Protein Therapeutics CDMO Company Insights

The major players operating across the market are focused on adopting inorganic strategic initiatives such as mergers, partnerships, acquisitions, etc. The prominent strategies adopted by companies are service launches, mergers & acquisitions/joint ventures, mergers, partnerships & agreements, expansions, and others to increase market presence & revenue and gain a competitive edge and drive market growth. Hence, increasing adoption of inorganic strategic initiatives is highly anticipated to boost the market share of prominent players operating across the market.

Key Recombinant Protein Therapeutics CDMO Companies

The following key companies have been profiled for this study on the recombinant protein therapeutics CDMO market:

• Richter-Helm BioLogics GmbH & Co. KG

• Lonza

• Catalent, Inc.

• FUJIFILM Biotechnologies

• WuXi Biologics

• Curia Global, Inc.

• KBI Biopharma

• HALIX B.V.

• 3PBIOVIAN

• Enzene Biosciences

Recent Developments

• In January 2026, WuXi Biologics entered a strategic partnership with HanchorBio to advance the production process of future-generation bi- and multi-functional fusion protein medicines.
• In March 2024, Lonza signed an agreement to acquire Roche's Genentech biologics manufacturing facility in Vacaville, California, for USD 1.2 billion in cash. The acquisition significantly expanded Lonza's large-scale biologics manufacturing capacity, strengthening its commercial-scale production capabilities for mammalian biologics, including recombinant protein therapeutics.

Global Recombinant Protein Therapeutics CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global recombinant protein therapeutics CDMO market report based on type, source, indication, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Growth Hormones

  • Interferons

  • Vaccines

  • Immunostimulating Agents

  • Others

• Source Outlook (Revenue, USD Million, 2021 - 2033)

  • Mammalian Systems

  • Microbial Systems

  • Others

• Indication Outlook (Revenue, USD Million, 2021 - 2033)

  • Oncology

  • Infectious Diseases

  • Immunological Disorders

  • Metabolic Disorders

  • Haematological Disorders

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait